Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) Gross Margin (2020 - 2025)

Journey Medical's Gross Margin history spans 6 years, with the latest figure at 64.81% for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin rose 190.0% year-over-year to 64.81%, compared with a TTM value of 65.49% through Dec 2025, up 336.0%, and an annual FY2025 reading of 65.83%, up 370.0% over the prior year.
  • Gross Margin for Q4 2025 was 64.81% at Journey Medical, down from 66.2% in the prior quarter.
  • The five-year high for Gross Margin was 85.27% in Q4 2023, with the low at 41.93% in Q4 2022.
  • Average Gross Margin over 5 years is 58.85%, with a median of 59.79% recorded in 2024.
  • Year-over-year, Gross Margin crashed -2318bps in 2021 and then surged 4333bps in 2023.
  • Tracing DERM's Gross Margin over 5 years: stood at 45.62% in 2021, then decreased by -8bps to 41.93% in 2022, then skyrocketed by 103bps to 85.27% in 2023, then dropped by -26bps to 62.92% in 2024, then grew by 3bps to 64.81% in 2025.
  • Per Business Quant, the three most recent readings for DERM's Gross Margin are 64.81% (Q4 2025), 66.2% (Q3 2025), and 67.09% (Q2 2025).